Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 10, 2025

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

82.5K

Tracking the tail.

Alex Friedlaender1, Stephen V Liu2, Alfredo Addeo3

  • 1Oncology, Geneva University Hospitals, Geneva, Switzerland.

Journal for Immunotherapy of Cancer
|September 5, 2020
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026
Same author

Decision making in intrathecal therapy for leptomeningeal disease.

Oncology·2026
Same author

Revue medicale suisse·2026
Same author

First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study.

JTO clinical and research reports·2026
Same journal

Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.

Journal for immunotherapy of cancer·2026
Same journal

Correction: CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell.

Journal for immunotherapy of cancer·2026
Same journal

DEA hypothesis: disinhibition, enhancing recognition, and alerting the host are the three pillars of effective cancer immunotherapy.

Journal for immunotherapy of cancer·2026
Same journal

Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy.

Journal for immunotherapy of cancer·2026
Same journal

Lithocholic acid-activated VDR in macrophages promotes HCC recurrence post-ablation via SOCS3-mediated suppression of CXCL16.

Journal for immunotherapy of cancer·2026
Same journal

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Journal for immunotherapy of cancer·2026
See all related articles

Front-line immune-checkpoint inhibitors are standard for advanced non-small cell lung cancer. Combination therapies show promise, but survival advantage requires further analysis of long-term data.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Immune-checkpoint inhibitors (ICIs) revolutionized advanced non-small cell lung cancer (NSCLC) treatment, particularly for PD-L1 positive tumors.
  • Despite ICI efficacy, many patients exhibit resistance, prompting the development of front-line combination strategies.

Purpose of the Study:

  • To review and analyze all available front-line ICI trials in NSCLC, including monotherapy and combination regimens.
  • To evaluate whether current combination therapies offer a survival advantage over single-agent ICI or chemotherapy.

Main Methods:

  • Systematic review and cross-trial analysis of published front-line immunotherapy trials in NSCLC.
  • Comparison of response rates and survival outcomes across different treatment modalities.

Main Results:

Keywords:
immunotherapylung neoplasms

More Related Videos

Tracking Rats in Operant Conditioning Chambers Using a Versatile Homemade Video Camera and DeepLabCut
08:32

Tracking Rats in Operant Conditioning Chambers Using a Versatile Homemade Video Camera and DeepLabCut

Published on: June 15, 2020

13.1K
An Alternant Method to the Traditional NASA Hindlimb Unloading Model in Mice
09:50

An Alternant Method to the Traditional NASA Hindlimb Unloading Model in Mice

Published on: March 10, 2011

21.1K

Related Experiment Videos

Last Updated: Dec 10, 2025

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

82.5K
Tracking Rats in Operant Conditioning Chambers Using a Versatile Homemade Video Camera and DeepLabCut
08:32

Tracking Rats in Operant Conditioning Chambers Using a Versatile Homemade Video Camera and DeepLabCut

Published on: June 15, 2020

13.1K
An Alternant Method to the Traditional NASA Hindlimb Unloading Model in Mice
09:50

An Alternant Method to the Traditional NASA Hindlimb Unloading Model in Mice

Published on: March 10, 2011

21.1K
  • Front-line combination therapies (chemoimmunotherapy, dual ICI) appear to yield numerically superior response rates compared to single-agent ICIs.
  • Head-to-head trial data comparing different combination strategies is lacking.
  • The ultimate survival benefit of combination therapies remains under investigation, necessitating long-term survival curve analysis.

Conclusions:

  • Current data suggests combination therapies are a viable front-line option for advanced NSCLC, but direct comparative evidence is limited.
  • The long-term survival tail of the curves is critical for determining the definitive benefit of these novel combinations.
  • Further head-to-head trials are needed to establish optimal front-line treatment standards in NSCLC.